UK markets closed

Corcept Therapeutics Incorporated (0I3Q.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
24.36+1.42 (+6.17%)
At close: 05:00PM GMT
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.53
52-week change 3N/A
S&P500 52-week change 3-7.75%
52-week high 30.00
52-week low 30.00
50-day moving average 3N/A
200-day moving average 3N/A

Share statistics

Avg vol (3-month) 3N/A
Avg vol (10-day) 3N/A
Shares outstanding 5115.47M
Implied shares outstanding 6N/A
Float 888.63M
% held by insiders 111.13%
% held by institutions 182.42%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2021
Most-recent quarter (mrq)30 Sept 2022

Profitability

Profit margin 29.39%
Operating margin (ttm)31.89%

Management effectiveness

Return on assets (ttm)14.17%
Return on equity (ttm)23.06%

Income statement

Revenue (ttm)397.62M
Revenue per share (ttm)3.67
Quarterly revenue growth (yoy)5.80%
Gross profit (ttm)360.7M
EBITDA 127.69M
Net income avi to common (ttm)116.81M
Diluted EPS (ttm)0.91
Quarterly earnings growth (yoy)13.60%

Balance sheet

Total cash (mrq)396.26M
Total cash per share (mrq)3.68
Total debt (mrq)1.71M
Total debt/equity (mrq)0.36
Current ratio (mrq)8.52
Book value per share (mrq)4.40

Cash flow statement

Operating cash flow (ttm)136.36M
Levered free cash flow (ttm)116.63M